June 2024
Eisai Seeks FDA Approval for Monthly IV Dosing of LEQEMBI for Alzheimer’s Disease Treatment
LEQEMBI, Eisai, FDA, Alzheimer’s disease, monthly IV dosing, subcutaneous autoinjector, lecanemab-irmb, Biogen
Kyowa Kirin Invests $530M in First North American Biologics Manufacturing Facility
Kyowa Kirin, biologics manufacturing, North America, investment, North Carolina
Asensus Surgical to be Acquired by KARL STORZ for $0.35 per Share in Cash
Asensus Surgical, KARL STORZ, acquisition, merger, surgical robotics, digital solutions, operating room, laparoscopy, LUNA system
FDA Expands Approval of GSK’s RSV Vaccine to Include At-Risk Adults Aged 50-59
RSV vaccine, GSK, FDA approval, at-risk adults, respiratory syncytial virus, Arexvy
Alumis Files for IPO to Fund Phase 3 Studies for Second-Generation TYK2 Inhibitor
Alumis, IPO, TYK2 inhibitor, Phase 3 studies, immune-mediated diseases, biotech, precision immunology
Oculis Announces Phase 2 Results for Licaminlimab in Dry Eye Disease, Despite Limited Statistical Significance
Oculis, Licaminlimab, Dry Eye Disease, Phase 2 Results, Statistical Significance
Skye Bioscience Abandons Eye Disease Pipeline, Shifts Focus to Obesity Treatment After Phase 2a Trial Failure
Skye Bioscience, eye disease, Phase 2a trial, obesity treatment, stock price, biotech company
Top 10 Pharmaceutical Drug Ad Spenders: A Review of the Latest Rankings
pharmaceutical drug ad spenders, top 10, AbbVie, Skyrizi, Rexulti, Dupixent, Rinvoq, Vraylar, Sotyktu, Jardiance, Ozempic, Caplyta, Opdivo
Italian Antitrust Agency Investigates Novartis, Biogen, and Others Over Lucentis Biosimilar
Italian Competition Authority, Novartis, Biogen, Samsung Bioepis, Genentech, Lucentis, Byooviz, Biosimilar, Antitrust Probe